[BMJ] S92FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD |
|
This post will be closed automatically in 2026-11-04 15:29
Reward10points
|
post
reply
points
3141
10
Use of extracorporeal shockwave therapies for athletes and physically active individuals: a systematic review
10
S92FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD
20
Adipophilin expression in skin lesions with clear cell histology
20
The strength每risk continuum: reframing muscular weakness as a clinically relevant risk marker
10
Reflex syncope: assessment and management
